Myomo (MYO) Non Operating Interest Expenses (2020)

Myomo's (MYO) quarterly Non Operating Interest Expenses came in at $12135.0 in Q3 2020, down 69.68% quarter-over-quarter from $40025.0 in Q2 2020.

Analysis

Myomo (MYO) Non Operating Interest Expenses (2020) Analysis & Trends

Myomo (MYO) has reported Non Operating Interest Expenses for 1 consecutive years, with $12135.0 the latest figure, recorded in Q3 2020.

For the quarter ending Q3 2020, Non Operating Interest Expenses changed N/A year-over-year to $12135.0; the trailing twelve-month figure through Dec 2020 stood at $218803.0 (changed N/A YoY), and the FY2020 full-year result was $218803.0, up 92.56% from the prior year.
Non Operating Interest Expenses retreated to $12135.0 in Q3 2020 per MYO's latest filing, from $40025.0 in the prior quarter.
Across five years, Non Operating Interest Expenses topped out at $166643.0 in Q1 2020 and bottomed at $12135.0 in Q3 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Interest Expenses (Qtr)
1	Abbott Laboratories	187.42 Bn	182.47 Bn	7.27 Bn	351.00 Mn
2	Intuitive Surgical	129.78 Bn	124.69 Bn	1.96 Bn	-
3	Medtronic	120.53 Bn	112.33 Bn	6.34 Bn	186.00 Mn
4	Stryker	116.28 Bn	112.80 Bn	4.50 Bn	141.00 Mn
5	Boston Scientific	69.29 Bn	68.99 Bn	3.85 Bn	96.00 Mn
6	Edwards Lifesciences	51.83 Bn	47.68 Bn	1.35 Bn	-
7	Alcon	34.36 Bn	32.91 Bn	1.68 Bn	-53.00 Mn
8	Dexcom	33.17 Bn	31.23 Bn	830.00 Mn	-
9	Steris	21.90 Bn	21.43 Bn	684.20 Mn	15.80 Mn
10	Myomo	54.96 Mn	35.99 Mn	-	-

Historic Data

Download Data